Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2024-02-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 first extraordinary general meeting of shareholders of Shenzhen Microchip Biotechnology Co., Ltd. It details the meeting date, attendance, voting results on specific proposals including share repurchase and capital reduction, and legal witness statements. The content focuses on the official voting results and procedural compliance rather than the full meeting materials or presentations. The document length is short (2136 characters) and it is clearly a resolution announcement with detailed voting outcomes. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-02-22 Chinese
关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the shareholding situation of the top ten shareholders and top ten unrestricted shareholders before a share repurchase plan. It references the board meeting approving the share repurchase plan and the upcoming extraordinary general meeting. The content focuses on shareholding details as of specific dates related to the share repurchase. There is no financial report, earnings data, or management discussion. The document is a formal announcement related to share repurchase and shareholder holdings, not a report or financial statement. This fits the category of Transaction in Own Shares (POS), which covers company announcements about share buybacks or related shareholding changes.
2024-02-18 Chinese
关于2021年限制性股票激励计划第二个归属期符合归属条件暨作废该部分限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the fulfillment of conditions for the second vesting period of the 2021 restricted stock incentive plan and the cancellation of part of the restricted stock. It details board and supervisory meetings, approval of stock incentive plans, performance conditions, and the cancellation of unvested shares due to resignation or voluntary waiver. The document is a formal disclosure about stock incentive plan status and related corporate governance matters, not a full financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement. It is a regulatory announcement about stock incentive plan execution and related corporate decisions. Therefore, it fits best under Regulatory Filings (RNS). The document length (5120 characters) and detailed content confirm it is not a mere report publication announcement or certification letter.
2024-02-06 Chinese
关于2024年度日常关联交易额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected daily related party transaction limits for the year 2024 by Shenzhen Microchip Biotechnology Co., Ltd. It details the board and supervisory committee approvals, independent director opinions, transaction categories, amounts, and related party information. The document is a formal announcement of a forecasted transaction limit rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but rather governance and compliance disclosures related to related party transactions. The document length is 4409 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2024-02-06 Chinese
关于召开2024年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2024 first extraordinary general meeting of shareholders for Shenzhen Microchip Biotechnology Co., Ltd. It includes details about the meeting date, voting methods, agenda items (such as share repurchase and capital reduction), and instructions for shareholders to attend and vote. It does not contain actual financial statements or results, but rather is an announcement of the meeting and related procedural information. The document length is about 3,024 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2024-02-06 Chinese
第二届董事会独立董事专门会议第一次会议决议
Board/Management Information Classification · 95% confidence The document is a resolution from the independent directors' special meeting of the board of Shenzhen Microcore Biotechnology Co., Ltd. It discusses approval of stock incentive plans, cancellation of unexercised stock rights, and approval of related party transaction limits for 2024. The content focuses on board-level decisions and approvals related to management and governance matters, specifically about stock incentive plans and related transactions. There is no financial statement, earnings data, or regulatory filing of financial results. The document is not an announcement of a report but a formal board/management decision record. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or announcement of a report publication.
2024-02-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.